Canaccord Genuity Maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Q1 Review; All Eyes on P3 Xiaflex Data
Tweet
Share
E-mailGet Alerts AUXL Hot Sheet
Price: $36.47 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 5
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 5
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (NASDAQ: AUXL) price target of $26.00.
Analyst, Salveen Richter, said, "AUXL reported a 1Q12 top- and bottom-line beat driven by strong Testim growth and lower-than-expected R&D expense. 1Q Xiaflex U.S. revenue of $12.6M was below consensus and CGe of $13.6M due to seasonality, while Testim total revenue of $58.7M was above consensus of $54.2M and CGe of $55.3M due to growth of the TRT gel market (+32% YoY, +9% QoQ) and Testim U.S. prescriptions (+21% YoY)."
"...Overall, Street focus remains on Xiaflex P3 top-line IMPRESS data in Peyronie's expected in June. While we view a higher-than-expected placebo response and variability due to the subjective disease bother co-primary endpoint as the key risks, we believe the studies have been optimized for success. We expect AUXL shares to trade to $25+ on positive data or $mid-teens on a negative read-out."
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $18.18 yesterday.
Analyst, Salveen Richter, said, "AUXL reported a 1Q12 top- and bottom-line beat driven by strong Testim growth and lower-than-expected R&D expense. 1Q Xiaflex U.S. revenue of $12.6M was below consensus and CGe of $13.6M due to seasonality, while Testim total revenue of $58.7M was above consensus of $54.2M and CGe of $55.3M due to growth of the TRT gel market (+32% YoY, +9% QoQ) and Testim U.S. prescriptions (+21% YoY)."
"...Overall, Street focus remains on Xiaflex P3 top-line IMPRESS data in Peyronie's expected in June. While we view a higher-than-expected placebo response and variability due to the subjective disease bother co-primary endpoint as the key risks, we believe the studies have been optimized for success. We expect AUXL shares to trade to $25+ on positive data or $mid-teens on a negative read-out."
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $18.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chipotle Mexican Grill (CMG) PT Raised to $3,050 at Stephens
- IDEX Corp (IEX) PT Lowered to $256 at Baird
- Meta Platforms Inc. (META) PT Lowered to $500 at Baird
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
